IBD Patient Pathway and Segmentation Analysis
Impact
The model provided a robust foundation for strategic planning, and upon validation, the project was expanded to three additional EU countries to capture regional variations in treatment practice and access.
Solution
phamax Advisory launched a two-phase program to quantify therapeutic opportunity with the first leg of project focusing on pathway design, sourcing insights from ECCO guidelines and following a structured data-sourcing approach. In the second phase, we integrated desk research, syndicated reports, and market research inputs to build a consolidated model outlining the therapeutic landscape, patient share across existing therapy classes, and evolving market dynamics. The analysis informed the competitive frame of reference and guided strategic positioning for the upcoming therapy.
Challenge
A global pharmaceutical company sought to map the Crohn’s Disease patient journey as part of their Inflammatory Bowel Disease (IBD) portfolio to identify target patient segments for its upcoming anti-TL1A therapy across key EU markets.
Additional questions?
How can we help?
Please submit your question here and we will respond as quickly as possible.
If your query relates to Privacy, please refer to the information and contact details listed in our Privacy Policy.
Fields marked with an asterisk (*) are required.